Incivek
(telaprevir)ApprovedSmall molecule
Vertex PharmaceuticalsTelaprevir is used to treat hepatitis C, a viral infection that affects the liver. It works by stopping the hepatitis C virus from reproducing in the body.[2] Incivek is currently approved and in use across 5 indications[4].[1]
Incivek is one of 168 small molecule programs targeting Viral Disease. It is currently in Approved.
5
Indications
63
Total Trials
0
Active Trials
167
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
1
Patents
Pipeline
Status by Indication[4][1]
Indication
Competition
Competitive Landscape
123 competitors in HIV Infection
#DrugCompanyPhaseTrials
1Incivek
Vertex PharmaceuticalsApproved
Retrovir
BBp Consulting, Inc
Approved
Videx
Bristol-Myers SquibbApproved
Norvir
AbbVieApproved
Tivicay
GSKApproved
Ziagen
GSKApproved
Viramune
Boehringer IngelheimApproved
Sustiva
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Approved
Olumiant
Eli LillyApproved
Lialda
TakedaApproved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Hepatitis C14 trials
Show 11 more trials
Chronic Hepatitis10 trials
Show 7 more trials
Interaction6 trials
Chronic Hepatitis C Virus Infection4 trials
Show 1 more trial
18 more indications
Liver Transplant3 trials
Efficacy and Safety3 trials
Combination Therapy2 trials
Trial2 trials
TED2 trials
Hepatic Impairment2 trials
HIV-11 trial
Tacrolimus1 trial
Adult Subject1 trial
HIV1 trial
Renal Impairment1 trial
Hepatocellular Carcinoma1 trial
ESS1 trial
Interleukin1 trial
Effectiveness1 trial
Comparative Effectiveness and Tolerability of Boceprevir vs Telaprevir
Completed·—·N/A·NCT02113631·50 enrolled
Regulatory
FDA Approval Timeline[5]
May 23, 2011
INCIVEK
NDA NDA201917
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Incivek drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for telaprevir. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]
- [7]
Details
Drug Info
Quick Facts
- Mechanism of Action
- Hepatitis C Virus Serine Protease, NS3/NS4A Inhibitor[3]
- Modality
- Small molecule[3]
- Highest Phase
- Approved[1]
- Company
Patent Landscape[6]
Patent Cliff
May 30, 2028
Earliest patent expiration — generic entry possible after this date
Patent #Expires
8431615May 30, 2028